Yale University: A combination of quercetal monotherapy and chemotherapy can effectively treat invasive endometrial cancer.

This article is for the original translational medicine network, please indicate the source: Cathy introduction: endometrial carcinoma, also known as uterine cancer, is a common cancer in the female reproductive system, the incidence rate is second only to cervical cancer. The incidence rate ofis increasing year by year in China.recently, scientists at Yale University have confirmed that a combination therapy can significantly improve the survival rate of patients with endometrial cancer.trastuzumab, a monoclonal antibody against human epidermal growth factor receptor-2 (HER2), blocks the growth of cancer cells by attaching itself to HER2. Recently, scientists at Yale Cancer Center (YCC) found that the combination of trastuzumab and chemotherapy can significantly improve the survival rate of cancer cells Survival rate of women with invasive endometrial carcinoma.the study was led by Dr. Alessandro Santin, a professor of Obstetrics and Gynecology and reproductive sciences at Yale University School of medicine and published online June 29 in clinical cancer research.corresponding author of the study entitled "randomized phase II trial of carboplatin – paclitaxel compared with carboplatin – paclitaxel – trastuzumab in advanced (stage III – IV) or recurrent urethane serous carcinomas that overexpress HER2 / neu (nct01367002): updated overall survival analysis" "This randomized, multi agency, phase 2 trial studied 58 women with uterine serous carcinoma (USC) whose tumors expressed high levels of HER2, which can cause a variety of cancers," Dr. Santin said."at the same time, he is also the leader of the disease joint research group of smilow cancer hospital and YCC gynecological tumor project.Dr. Alessandro Santin in this study, patients in the control group received the standard chemotherapy regimen of carboplatin and paclitaxel, and the experimental group received the same chemotherapy regimen followed by trastuzumab.(trastuzumab targeting HER2 can improve the prognosis of breast cancer women with high HER2 expression.) the results showed that trastuzumab combination therapy was particularly effective in 41 women with advanced stage III and IV USC who received treatment for the first time.the average progression free survival (PFS) of women receiving this treatment doubled from 9 months in the control group to 18 months in the control group. "This is unprecedented for this cancer," Santin said."he added:" it is important that there is no difference in toxicity between the experimental group and the control group. Trastuzumab is a humanized antibody, a natural product of the human body, and has a very good tolerance."in the United States, more than 65650 women are diagnosed with endometrial cancer every year, and more than 12590 people die from the disease.Santin said: "these numbers are likely to double in the next decade as the U.S. population ages and obesity rates rise.although USC accounts for only 3% to 10% of all endometrial cancer cases, it kills more than 40% of patients because of its strong invasiveness."in addition, in the 17 women with recurrent USC in this study, the combination therapy prolonged the disease-free interval, but did not significantly improve the survival rate compared with the standard chemotherapy regimen.Santin said: "these are patients with recurrent metastatic cancer, and it is likely that their tumor burden is very high and uneven, so that the tumor is also resistant to trastuzumab. "in 2018, the national comprehensive cancer network (NCCN) in the United States reviewed the preliminary data of phase 2 trials, and adopted the new treatment of chemotherapy / trastuzumab in HER2 positive USC women as a treatment guideline. NCCN is widely recognized as the standard setting agency of clinical guidelines for cancer in the United States. Santin said: "with these NCCN guidelines, everyone starts using this therapy.". now that the final results of the trial have been published, he expects the combination therapy to be more widely used worldwide. Ref.: [1] Amanda fader et al, randomized phase II trial of carboplatin – paclitaxel compared with carboplatin – paclitaxel – trastuzumab in advanced (stage III – IV) or recurrent urethane serous carinomas that overexpress HER2 / neu (nct01367002): updated overall survival analysis, clinical cancer research (2020) DOI: 10.1158/1078-0432.CCR-20-0953 [2] [3] recommended reading: anti epidemic, transforming medical network content team report: [JAMA] large-scale prospective study and analysis showed that smoking cessation, alcohol restriction and garlic consumption has the final say. [new findings] Chinese studies have shown that maternal obesity increases the chance of future generations to develop liver cancer